CONCORD, Mass., Jan. 9, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, today announced positive topline results ...
AUSTIN, Texas, April 21, 2026 (GLOBE NEWSWIRE)-- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the U.S. Food and ...
Cristcot announced the launch of Sephure, the first disposable rectal suppository applicator. With the applicator, patients can administer a suppository in less than 5 seconds. Sephure is a disposable ...
April 11, 2012 — A single indomethacin suppository administered to patients immediately after endoscopic retrograde cholangiopancreatography (ERCP) appears to significantly reduce the risk for ...
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines: You have to credit our authors. You ...
Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...
-- Prescription Drug User Fee Act (PDUFA) target date of October 2026 -- -- Submission supported by CESSA Phase 3 trial results demonstrating statistically significant rates of clinical remission in ...
Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results